Skip to main content
. 2022 Aug 23;13:20406207221115005. doi: 10.1177/20406207221115005

Figure 3.

Figure 3.

Myeloid panel sequencing of EM, germline, and bone marrow samples. (a) Myeloid panel sequencing revealed recurrent RUNX1:c.497_498insGA frameshift mutation in exon 4 in all extramedullary sites, but not in the bone marrow aspirate or in germline DNA. (b) ASXL1:c.3306G>T point mutation in exon 13 was only detected in the retroperitoneal and latest EM site, while bone marrow, germline DNA, and other EM of the patient showed no ASXL1 aberration at previous AML disease stages.